Skip to main content

Table 2 Overview of the acute phase interview

From: Optimization of measurement-based care (OMBC) for depression based on all-round and continuous assessment: rationale and protocol for a multicenter randomized control clinical trial

  Acute phase
0 Week 2, day 14 (± 3) Week 4, day 28 (± 3) Telephone interview (week 6) Week 8, day 56 (± 3) Telephone interview, week 10 (for patients who change drugs in week 4) Week 12 (± 7)/early termination
Informed consent ×       
Inclusion/exclusion criteria ×       
General data ×       
Medical history and mental symptoms ×       
MINI ×       
Somatic and neurological examination ×       
Vital signs/weight ×   ×   ×   
QIDS-SR 16 × × × × × × ×
FIBSER × × × × × × ×
PDQ-9 ×   ×   ×   ×
SDS ×   ×   ×   ×
FBS ×   ×   ×   ×
Q-LES-Q-SF ×   ×   ×   ×
HAMD-17 ×   ×   ×   ×
YMRS ×   ×   ×   ×
Acceptability/feasibility   × ×   ×   ×
Adverse reactions × × × × ×   ×
Biological sample collection × ×      ×
  1. MINI Mini-International Neuropsychiatric Interview, QIDS-SR 16 16-item Quick Inventory of Depressive Symptomatology–Self-Report, FIBSER Frequency, Intensity, and Burden of Side Effects Rating scale, PDQ-9 Patient Health Questionnaire-9, SDS Self-Rating Depression Scale, FBS Family Burden Scale of Disease, Q-LES-Q-SF Quality of Life Enjoyment and Satisfaction Questionnaire–Short Form, HAMD-17 17-Item Hamilton Rating Scale for Depression, YMRS Young Mania Rating Scale